FOLH1 and prostate carcinoma: <h4>Background</h4>Patients with prostate cancer who develop androgen pathway modulation resistant (APMR) disease face lethal outcomes despite advances in androgen receptor-pathway inhibitors, chemotherapy, and PSMA-directed radioligands.